Pacira BioSciences stock at USD 36.34 on October 16, 2026, 0.90 percent below high

Published on 10/17/2026 at 21:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 192.40 million. Pacira BioSciences stock was last at USD 36.34 on October 16, 2026, up 0.03 percent on Nasdaq.

Trading range and operating scale

The October 16, 2026 quote stood 0.90 percent below Pacira BioSciences' USD 36.67 52-week high.
Second-quarter revenue reached USD 192.40 million, a 6.20 percent year-over-year increase.
Pacira BioSciences stock was last at USD 36.34 on Nasdaq on October 16, 2026, up 0.03 percent on the day.

PCRX, US6951271005, Illustration mit AI erstellt.

Pacira BioSciences stock was last at USD 36.34 on October 16, 2026, just 0.90 percent below its 52-week high of USD 36.67. The quote was up 0.03 percent on Nasdaq during the session.

Second-quarter revenue reached USD 192.40 million

Revenue provides the clearest operating counterpoint to the stock's deal-driven price level. Zacks reported that second-quarter 2026 revenue rose 6.20 percent year over year to USD 192.40 million. Adjusted earnings per share reached USD 0.73, above the USD 0.64 consensus estimate.

Pacira stock stays near its yearly high

The latest USD 36.34 quote sits between the USD 18.80 52-week low and the USD 36.67 high. The distance to the high is 0.90 percent, while the year-to-date gain was 6.70 percent in the latest reported market overview. Trading volume reached 960,886 shares against an average of 1,206,287 shares.

The price is also close to the USD 36.50 cash consideration discussed in recent market coverage. MarketBeat reported that Royal Bank of Canada lifted its target from USD 25.00 to USD 36.50 on October 9, 2026, while keeping a sector perform rating.

Valuation and trading comparisons

Pacira BioSciences had a market capitalization of USD 1.4 billion and a price-to-earnings ratio of 103.44 as of October 16, 2026. The valuation differs sharply across the specialty pharmaceutical group, making earnings delivery and the next corporate update more important than a simple price comparison.

Comparison with peers

Pacira BioSciences (Nasdaq, USD): plus 0.03 percent, P/E 103.44, market capitalization USD 1.4 billion
Collegium Pharmaceutical (Nasdaq, USD): plus 0.04 percent, P/E 18.70, market capitalization USD 755.0 million
Axsome Therapeutics (Nasdaq, USD): minus 2.87 percent, P/E minus 41.90, market capitalization USD 8.2 billion

Price remains the key reference

Pacira's latest Nasdaq quote was USD 36.34 on October 16, 2026 at 4:00 p.m. ET, up 0.03 percent on the day. The stock's position near USD 36.67 leaves little distance to the yearly peak, while the second-quarter revenue increase gives investors a separate operating measure.

Market context: Market report Nasdaq Composite.

More news and analyses on Pacira BioSciences stock